ZIMLAB
Zim Laboratories Limited (ZIMLAB) Stock Analysis
Zim Laboratories Limited develops pharmaceutical formulations including oral thin films and generics for India and exports. It focuses on patient-friendly dosage forms and contract manufacturing for partners. The company operates manufacturing in central India. It is listed on Indian stock exchanges.
Healthcare › Drug Manufacturers - Specialty & Generic
₹150.50
+9.82% 1W | +105.90% 52W
Market Cap
806 CR
P/E Ratio
183.5
52W High
₹153.9
52W Low
₹59.3
Div. Yield
0%
Beta
0.8
50 DMA
₹125.8
200 DMA
₹97.6
Profit Margin
0.9%
Inst. Own.
1.2%
🔥 APPROACHING RESISTANCE
🔥 APPROACHING RESISTANCE
Fundamentals
Profit & Loss
| Metric | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 67.44 | 85.83 | 96.29 | 117.86 | 81.82 | 92.14 | 96.33 | 108.73 | 71.76 | 88.71 | 108.66 | 105.27 | 94.18 |
| Expenses | 62.62 | 76.50 | 84.75 | 102.21 | 73.78 | 82.61 | 84.77 | 94.13 | 67.51 | 82.95 | 95.85 | 98.08 | 91.73 |
| Operating Profit | 4.82 | 9.33 | 11.54 | 15.65 | 8.04 | 9.53 | 11.56 | 14.60 | 4.25 | 5.76 | 12.81 | 7.19 | 2.45 |
| OPM % | 7.15% | 10.87% | 11.98% | 13.28% | 9.83% | 10.34% | 12.00% | 13.43% | 5.92% | 6.49% | 11.79% | 6.83% | 2.60% |
| Other Income | 1.12 | 1.42 | 1.11 | 1.53 | 1.00 | 1.32 | 1.75 | 1.71 | 1.48 | 2.04 | 1.70 | 6.16 | 0.99 |
| Interest | 1.73 | 1.22 | 1.70 | 2.28 | 2.86 | 2.89 | 2.73 | 2.91 | 3.30 | 3.16 | 3.43 | 3.31 | 3.64 |
| Depreciation | 4.03 | 4.09 | 3.94 | 3.91 | 4.94 | 5.00 | 4.88 | 5.29 | 4.86 | 4.98 | 5.03 | 5.10 | 5.37 |
| Profit before tax | 0.18 | 5.44 | 7.01 | 10.99 | 1.24 | 2.96 | 5.70 | 8.11 | -2.43 | -0.34 | 6.05 | 4.94 | -5.57 |
| Tax % | -22.22% | 23.71% | 31.81% | 26.48% | 27.42% | 19.59% | 30.00% | 39.70% | -22.63% | 23.53% | 27.27% | 24.29% | -28.01% |
| Net Profit | 0.23 | 4.15 | 4.78 | 8.09 | 0.90 | 2.38 | 4.00 | 4.88 | -1.87 | -0.42 | 4.40 | 3.74 | -4.02 |
| EPS in Rs | 0.05 | 0.85 | 0.98 | 1.66 | 0.18 | 0.49 | 0.82 | 1.00 | -0.38 | -0.09 | 0.90 | 0.70 | -0.75 |
| Metric | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 266 | 269 | 235 | 273 | 335 | 278 | 307 | 333 | 399 | 367 | 379 | 374 | 397 |
| Expenses | 278 | 239 | 203 | 238 | 293 | 255 | 268 | 292 | 347 | 326 | 335 | 344 | 369 |
| Operating Profit | -12 | 30 | 32 | 35 | 42 | 23 | 40 | 41 | 52 | 41 | 44 | 30 | 28 |
| OPM % | -4.4% | 11% | 13% | 13% | 13% | 8% | 13% | 12% | 13% | 11% | 12% | 8% | 7% |
| Other Income | 2 | -2 | 5 | 9 | 2 | 5 | -3 | 4 | 6 | 5 | 6 | 11 | 11 |
| Interest | 10 | 14 | 10 | 9 | 11 | 13 | 11 | 8 | 6 | 7 | 11 | 13 | 14 |
| Depreciation | 7 | 9 | 9 | 10 | 11 | 14 | 16 | 16 | 17 | 16 | 20 | 20 | 20 |
| Profit before tax | -27 | 5 | 18 | 25 | 22 | 0 | 10 | 21 | 35 | 24 | 18 | 8 | 5 |
| Tax % | -19% | 5% | -6% | 23% | 30% | -4,600% | 28% | 31% | 31% | 27% | 32% | 29% | |
| Net Profit | -22 | 5 | 19 | 19 | 15 | 3 | 7 | 15 | 24 | 17 | 12 | 6 | 4 |
| EPS in Rs | 3.17 | 0.68 | 1.50 | 2.99 | 5.01 | 3.54 | 2.50 | 1.09 | 0.76 | ||||
| Dividend Payout % | 0% | 16% | 4% | 4% | 5% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
Growth — CAGR
| Metric | 3Y | 5Y | 10Y |
|---|---|---|---|
| Revenue CAGR | -2.0% | 4.0% | 3.0% |
| Profit CAGR | -44.0% | -17.0% | -7.0% |
Shareholding Pattern
Promoters33.26%
FIIs0.03%
DIIs0.24%
Public66.46%
Promoters33.26%
DIIs0.24%
Public66.52%
Promoters33.26%
FIIs0.02%
DIIs0.20%
Public66.52%
Promoters30.35%
DIIs0.07%
Public69.57%
Promoters30.36%
FIIs0.03%
DIIs1.34%
Public68.28%
Promoters33.26%
Public66.74%
Promoters33.26%
FIIs0.01%
Public66.74%
Promoters33.26%
FIIs0.01%
DIIs0.24%
Public66.49%
Promoters30.35%
DIIs0.07%
Public69.57%
Promoters30.36%
FIIs0.03%
DIIs1.34%
Public68.28%
ZIMLAB
Holdings Analysis
Key strengths & risk signals
57
Overall
27
Fundamental
87
Technical
Risks (1)
Cannot calculate PEG - insufficient growth data.
Strengths (3)
BULLISH TREND! 50-day average (125.8) is above 200-day average (97.6) - positive signal.
EXCELLENT YEAR! Stock gained 105.9% in the last year.
BULLISH SENTIMENT! In last 30 days: 16 up days, 14 down days. Avg volume on up days: 240,439 vs down days: 98,363. Ratio: 2.44x
Fundamental & Technical Analysis
57Overall
27Fundamental
87Technical
Fundamental Breakdown
Growth Quality
4/30
Revenue CAGR: -2.5% (DECLINING, 2/15). Profit CAGR: -37.9% (DECLINING, 2/15).
Profit Margin
2/10
LOW MARGIN! 0.9% profit margin - thin profits.
PEG Valuation
1/10
Cannot calculate PEG - insufficient growth data.
Dividend Yield
3/10
NEGLIGIBLE DIVIDEND! 0% yield - little to no income.
Debt to Equity
10/10
VERY LOW DEBT! D/E of 0.00 - excellent financial health.
Public Holding
5/20
TOO MUCH PUBLIC HOLDING! 66.69% public ownership - higher volatility risk.
Stability Index
2/10
CAUTION! Company made loss in last quarter. Be careful.
Technical Breakdown
Moving Averages
12/10
BULLISH TREND! 50-day average (125.8) is above 200-day average (97.6) - positive signal.
Price Position
8/10
STRONG POSITION! Current price (150.5) is above both moving averages.
Trend Pattern
10/20
AT RESISTANCE! Stock is at key resistance level.
52W Performance
10/10
EXCELLENT YEAR! Stock gained 105.9% in the last year.
Volume Sentiment
30/30
BULLISH SENTIMENT! In last 30 days: 16 up days, 14 down days. Avg volume on up days: 240,439 vs down days: 98,363. Ratio: 2.44x
RSI
3/5
BULLISH! RSI at 67.1 - positive momentum.
52W Range
5/5
STRONG! Trading at 96.4% of 52W range - near yearly highs.
Momentum
5/5
STRONG MOMENTUM! Price has grown across all timeframes - up 9.8% (1 week), 12.8% (1 month), 32.4% (3 months). Momentum is accelerating.
Beta
4/5
BELOW MARKET! Beta of 0.80 - slightly less volatile than market.
ZIMLAB
Concall / Investor Presentation
Earnings call transcripts & AI summaries
| Quarter | Concall | Summary |
|---|---|---|
| Q1FY272026-08-12 | Concall PDF | |
| Q4FY262026-05-23 | Concall PDF | |
| Q3FY262026-02-17 | Concall PDF | |
| Q2FY262025-11-17 | Concall PDF |
Peer Comparison
Healthcare · Drug Manufacturers - Specialty & Generic · 8 stocks
| Stock | Price | P/E | Profit Margin | Revenue CAGR 5Y | Profit CAGR 5Y | 52W Change | Stock Strength | Trendline | YoY Profit | QoQ Profit | YoY Revenue | QoQ Revenue |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ZIMLAB | ₹150.50 | 183.5 | 0.9% | -2.5% | -37.9% | +105.9% | 57 | APPROACHING RESISTANCE | +110.5% | -208.1% | +31.2% | -10.5% |
| ANUHPHR | ₹82.00 | 18.6 | 5.7% | 13.5% | 4.3% | +4.0% | 64 | BREAKDOWN | +37.3% | -2.6% | +3.9% | -4.1% |
| KILITCH | ₹241.60 | 27.4 | 12.7% | 19.2% | 42.4% | +41.9% | 84 | BREAKOUT | -3.3% | -80.0% | +4.2% | -49.9% |
| AMANTA | ₹187.40 | 45.1 | 5.0% | 3.3% | – | +54.5% | 61 | BREAKDOWN | -5.7% | -40.0% | +5.4% | -10.6% |
| WANBURY | ₹196.40 | 12.1 | 8.6% | 8.9% | – | -21.7% | 51 | APPROACHING SUPPORT | -76.3% | -85.3% | +1.5% | +0.6% |
| VALIANTLAB | ₹119.80 | 42.6 | 5.2% | -10.7% | – | +41.7% | 60 | BREAKDOWN | +1,072.2% | +1,072.2% | +146.4% | +25.3% |
| BAFNAPH | ₹418.00 | 127.1 | 5.5% | 9.3% | -0.7% | +152.4% | 66 | BREAKOUT | -97.1% | -96.3% | -23.1% | -37.0% |
| THEMISMED | ₹108.60 | 25.1 | 12.1% | -0.4% | -72.8% | -16.1% | 53 | BREAKDOWN | -273.2% | +176.4% | -10.9% | +13.7% |
Data from TradeAlone · Updated daily
